Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does MEROPENEM Cause Malignant neoplasm progression? 27 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 27 reports of Malignant neoplasm progression have been filed in association with MEROPENEM (Meropenem). This represents 0.2% of all adverse event reports for MEROPENEM.

27
Reports of Malignant neoplasm progression with MEROPENEM
0.2%
of all MEROPENEM reports
17
Deaths
20
Hospitalizations

How Dangerous Is Malignant neoplasm progression From MEROPENEM?

Of the 27 reports, 17 (63.0%) resulted in death, 20 (74.1%) required hospitalization, and 4 (14.8%) were considered life-threatening.

Is Malignant neoplasm progression Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for MEROPENEM. However, 27 reports have been filed with the FAERS database.

What Other Side Effects Does MEROPENEM Cause?

Drug ineffective (2,802) Off label use (1,572) Condition aggravated (706) Pyrexia (669) Multiple organ dysfunction syndrome (655) Drug reaction with eosinophilia and systemic symptoms (626) Septic shock (613) Drug resistance (539) Acute kidney injury (522) Rash (437)

What Other Drugs Cause Malignant neoplasm progression?

PEMBROLIZUMAB (10,111) NIVOLUMAB (9,363) ENZALUTAMIDE (4,696) CARBOPLATIN (4,177) EVEROLIMUS (3,789) PACLITAXEL (3,484) LETROZOLE (3,445) IPILIMUMAB (3,296) FULVESTRANT (3,221) LENVATINIB (2,929)

Which MEROPENEM Alternatives Have Lower Malignant neoplasm progression Risk?

MEROPENEM vs MEROPENEM ANHYDROUS MEROPENEM vs MESALAMINE MEROPENEM vs MESNA MEROPENEM vs METAMIZOLE MEROPENEM vs METARAMINOL

Related Pages

MEROPENEM Full Profile All Malignant neoplasm progression Reports All Drugs Causing Malignant neoplasm progression MEROPENEM Demographics